These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30400799)

  • 1. Status of programmed death-ligand 1 expression in sarcomas.
    Park HK; Kim M; Sung M; Lee SE; Kim YJ; Choi YL
    J Transl Med; 2018 Nov; 16(1):303. PubMed ID: 30400799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
    Torabi A; Amaya CN; Wians FH; Bryan BA
    Pathology; 2017 Aug; 49(5):506-513. PubMed ID: 28688724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
    Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
    Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas.
    Zhang Y; Chen Y; Papakonstantinou A; Tsagkozis P; Linder-Stragliotto C; Haglund F
    Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
    Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B
    BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes.
    Vargas AC; Maclean FM; Sioson L; Tran D; Bonar F; Mahar A; Cheah AL; Russell P; Grimison P; Richardson L; Gill AJ
    PLoS One; 2020; 15(4):e0222551. PubMed ID: 32294103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions.
    Lee K; Song JS; Kim JE; Kim W; Song SY; Lee MH; Chung HW; Cho KJ; Lee JS; Ahn JH
    Eur J Surg Oncol; 2020 Jul; 46(7):1287-1293. PubMed ID: 32127249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PD-L1/PD-1 axis expression on tumor-infiltrating immune cells and tumor cells in pediatric rhabdomyosarcoma.
    Gabrych A; Pęksa R; Kunc M; Krawczyk M; Izycka-Swieszewska E; Biernat W; Bień E
    Pathol Res Pract; 2019 Dec; 215(12):152700. PubMed ID: 31704149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas.
    Kelany M; Barth TF; Salem D; Shakweer MM
    Pathol Oncol Res; 2021; 27():1609804. PubMed ID: 34276259
    [No Abstract]   [Full Text] [Related]  

  • 11. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
    Paydas S; Bagir EK; Deveci MA; Gonlusen G
    Med Oncol; 2016 Aug; 33(8):93. PubMed ID: 27421997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas.
    Hashimoto K; Nishimura S; Ito T; Akagi M
    Eur J Histochem; 2021 Jul; 65(3):. PubMed ID: 34218652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
    Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
    Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
    Keung EZ; Burgess M; Salazar R; Parra ER; Rodrigues-Canales J; Bolejack V; Van Tine BA; Schuetze SM; Attia S; Riedel RF; Hu J; Okuno SH; Priebat DA; Movva S; Davis LE; Reed DR; Reuben A; Roland CL; Reinke D; Lazar AJ; Wang WL; Wargo JA; Tawbi HA
    Clin Cancer Res; 2020 Mar; 26(6):1258-1266. PubMed ID: 31900276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Consistency of PD-L1 immunohistochemical detection platforms in biopsy samples with advanced lung adenocarcinoma: a multicenter study].
    Yuan P; Guo CY; Li Y; Jiang LL; Liu YP; Liu XY; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):840-844. PubMed ID: 30423607
    [No Abstract]   [Full Text] [Related]  

  • 19. Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas.
    Asanuma K; Nakamura T; Hayashi A; Okamoto T; Iino T; Asanuma Y; Hagi T; Kita K; Nakamura K; Sudo A
    Sci Rep; 2020 Jun; 10(1):9077. PubMed ID: 32493964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
    Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
    BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.